Pds biotech announces presentation of pds0101 data at the 2022 multidisciplinary head and neck cancers symposium

Florham park, n.j., jan. 12, 2022 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing novel cancer therapies based on the company's proprietary versamune® t-cell activating technology, today announced that the initial safety data from its versatile-002 study has been accepted for presentation at the 2022 multidisciplinary head and neck cancers symposium being held february 24-26, 2022, at the jw marriott phoenix desert ridge resort and spa, phoenix, az.
PDSB Ratings Summary
PDSB Quant Ranking